SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ:ILMN) today announced that its MiSeq™Dx Sequencing System received the approval certificate from the China National Drug Administration (CNDA). This is Illumina’s first CNDA-cleared, next-generation sequencing (NGS) system in China. In accordance with the clearance, Illumina can now market and sell the MiSeqDx Sequencing System to hospitals and other medical institutions... Read more
SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (Nasdaq: ILMN) today announced the pricing of an offering of $650 million aggregate principal amount of its 0.0% convertible senior notes due 2023 (the “Notes”). The Notes are being offered to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Illumina has... Read more
SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (Nasdaq: ILMN) today announced its intention to offer, subject to market and other conditions, approximately $650 million aggregate principal amount of convertible senior notes due 2023 (the “Notes”). Illumina also intends to grant the initial purchasers a 30-day option to purchase up to an additional $100 million in aggregate principal amount... Read more
SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conferences, and invited investors to participate via webcast. Goldman Sachs Global Healthcare Conference in Rancho Palos Verdes, CATuesday, June 12, 2018 at 10:00 am Pacific Time William Blair & Company Growth Stock Conference in Chicago, ILWednesday, June 13,... Read more
SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) today announced that it acquired Edico Genome, the leading provider of data analysis acceleration solutions for next-generation sequencing (NGS). Edico Genome’s DRAGEN® Bio-IT Platform (DRAGEN) uses field programmable gate array (FPGA) technology in conjunction with proprietary software algorithms to reduce both data footprint and time to results. DRAGEN can be run on... Read more
SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conference, and invites investors to participate via webcast. Bank of America Merrill Lynch Health Care Conference in Las Vegas, NVWednesday, May 16, 2018 at 3:40 pm Pacific Time The live webcast can be accessed in the Investor Relations... Read more
NEW YORK & SAN DIEGO–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) and Illumina, Inc. (NASDAQ: ILMN) today announced a collaboration that will utilize Illumina’s next-generation sequencing (NGS) technology to develop and globally commercialize in-vitro diagnostic (IVD) assays in support of Bristol-Myers Squibb’s oncology portfolio. The companies plan to develop a diagnostic version of the Illumina TruSight Oncology... Read more
NEW ORLEANS, April 13, 2018 /PRNewswire/ — Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Illumina, Inc. (Nasdaq: ILMN). During the first two quarters of 2016, the Company, which provides genetic sequencing products to customers in the... Read more
SAN DIEGO & STAMFORD, Conn.–(BUSINESS WIRE)–Illumina, Inc. (Nasdaq: ILMN) and Loxo Oncology (Nasdaq: LOXO) today announced a global strategic partnership to develop and commercialize a multi-gene panel for broad tumor profiling, resulting in a distributable, next-generation sequencing (NGS) based companion diagnostic (CDx) with a pan-cancer indication. The co-development partnership will seek approval for a version... Read more
SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ:ILMN) announced today the appointment of Dr. Phil Febbo, a leading physician scientist, as Chief Medical Officer (CMO), starting March 26, 2018. In his new role, Dr. Febbo will be responsible for developing and executing on the Company’s medical strategy to drive genomic testing into healthcare practice. “We are very excited to welcome... Read more